Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auranofin for Amebiasis and Giardiasis
NCT02736968Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of auranofin in amebiasis, giardiasis, sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2016; status: completed.
02
Drugs
auranofin
03
Conditions
amebiasisgiardiasis
Beyond the preview
Go deeper on NCT02736968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736968.